Blood‐based biomarkers enrich for amyloid positive participants, reducing patient burden in PROGRESS‐AD, a phase 2 clinical trial for early Alzheimer's disease

Abstract

Background: Enrollment in clinical trials for early Alzheimer's disease is typically slow due to low rates of amyloid positivity but essential confirmatory testing using CSF biomarkers or amyloid PET imaging increases patient burden and operational challenges.

The paper